Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
J. Randolph Hecht, Young Suk Park, Josep Tabernero, Myung Ah Lee, Soo Hyun Lee, A.C. Virgili Manrique, Marc Van den Eynde, Elisa Fontana, Marwan Fakih, Gholamreza Asghari, Jane So, Alexander Stein, Olivier Dubreuil, Lubomir Bodnar, Cixin He, Guan Wang, Robina Smith, Cathy Eng, Anwaar Saeed
Topics & Concepts
RegorafenibAtezolizumabMedicineRefractory (planetary science)Colorectal cancerInternal medicineOncologyPhases of clinical researchClinical trialOpen labelPhase (matter)Randomized controlled trialMEDLINEColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersColorectal Cancer Surgical Treatments